Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: An overview of safety considerations from the Research on Adverse Drug Events and Reports project

Bone Marrow Transplantation

Volumn 40, Issue 3, 2007, Pages 185-192

  Tigue, C C ^a,b   McKoy, J M ^a   Evens, A M ^a   Trifilio, S M ^a   Tallman, M S ^a   Bennett, C L ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTINEOPLASTIC AGENT; AZACITIDINE; GRANULOCYTE COLONY STIMULATING FACTOR; IBUPROFEN; PARACETAMOL;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LUNG INJURY; AUTOIMMUNE DISEASE; BONE PAIN; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER REGISTRY; CANCER RISK; CLINICAL TRIAL; DONOR; DRUG ACTIVITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; HEART INFARCTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERTHYROIDISM; LONG TERM CARE; MALIGNANT NEOPLASTIC DISEASE; MYELODYSPLASIA; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NEWBORN SEPSIS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; SHWACHMAN SYNDROME; SPLEEN RUPTURE; STROKE; THYROID DISEASE; VASCULAR DISEASE;

BONE AND BONES; CHRONIC DISEASE; DATABASES, FACTUAL; DRUG TOXICITY; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; HYPERSENSITIVITY; LEUKEMIA, MYELOID, ACUTE; LUNG; LUNG DISEASES; NEOPLASMS; NEUTROPENIA; PAIN; REGISTRIES; RISK FACTORS; SPLENIC RUPTURE; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; VASCULAR DISEASES;

EID: 34547182356     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705722     Document Type: Review

References (64)

1. Pulsipher MA, Nagler A, Iannone R, Nelson RM. Weighing the risks of G-CSF administration, leukopheresis, and standard marrow harvest: ethical and safety considerations for normal pediatric hematopoietic cell donors. Pediatr Blood Cancer 2006; 46: 422-433.
2. Horowitz MM, Confer DL. Evaluation of hematopoietic stem cell donors. Hematology American Society of Hematology Education Program Book, 2005, pp 469-475.
3. Bennett CL, Evens AM, Andritsos LA, Balasubramanian L, Mai M, Fisher M et al. Hematologic malignancies developing in previously healthy individuals who received hematopoietic growth factors: Report from the Research on Adverse Drug Events and Reports (RADAR) project. Br J Haematol 2006; 135: 642-650.
4. Verdijk RM. Thrombopoietin in healthy donors. Blood 2002; 99 3867, author reply 3867-3868.
5. Donadieu J. Is G-CSF-mobilized peripheral stem cell harvest harmful? Pediatr Blood Cancer 2006; 48: 594-595.
6. Pulsipher M. RE: Is G-CSF-mobilized peripheral stem cell harvest harmful? Pediatr Blood Cancer 2006; 48: 595-596.
7. Pentz RD. Healthy sibling donation of G-CSF primed stem cells: A call for research. Pediatr Blood Cancer 2006; 46: 407-408.
8. Goldman JM, Madrigal JA, Pamphilon D. Possible harmful effects of short course granulocyte colony-stimulating factor in normal donors. Br J Haematol 2006; 135: 651-652.
9. Touw IP, Bontenbal M. Granulocyte colony-stimulating factor: Key (f)actor or innocent bystander in the development of secondary myeloid malignancy? J Natl Cancer Inst 2007; 99: 183-186.
10. Bennett CL, Nebeker JR, Lyons EA, Samore MH, Feldman MD, McKoy JM et al. The Research on Adverse Drug Events and Reports (RADAR) project. J Am Med Assoc 2005; 293: 2131-2140.
11. Bennett C, Nebeker JR, Yarnold PR, Tigue CC, Dorr DA, McKoy JM et al. Evaluation of serious adverse drug reactions: A proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers. Arch Intern Med 2007; 167: 1041-1049.
12. Anderlini P, Donato M, Chan KW, Huh YO, Gee AP, Lauppe MJ et al. Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: The MD Anderson Cancer Center experience. Transfusion 1999; 39: 555-560.
13. Beelen DW, Ottinger H, Kolbe K, Ponisch W, Sayer HG, Knauf W et al. Filgrastim mobilization and collection of allogeneic blood progenitor cells from adult family donors: First interim report of a prospective German multicenter study. Ann Hematol 2002; 81: 701-709.
14. Martino M, Morabito F, Callea I, Pontari A, Irrera G, Pucci G et al. Harvesting peripheral blood progenitor cells from healthy donors with a short course of recombinant human granulocyte-colony-stimulating factor. Transfus Med 2005; 15: 323-328.
15. Martino M, Console G, Irrera G, Callea I, Condemi A, Dattola A et al. Harvesting peripheral blood progenitor cells from healthy donors: retrospective comparison of filgrastim and lenograstim. J Clin Apher 2005; 20: 129-136.
16. Murata M, Harada M, Kato S, Takahashi S, Ogawa H, Okamoto S et al. Peripheral blood stem cell mobilization and apheresis: Analysis of adverse events in 94 normal donors. Bone Marrow Transplant 1999; 24: 1065-1071.
17. Kroschinsky F, Hundertmark J, Mauersberger S, Hermes M, Poppe-Thiede K, Rutt C et al. Severe autoimmune hyperthyroidism after donation of growth factor-primed allogeneic peripheral blood progenitor cells. Haematologica 2004; 89: ECR05.
18. de Luis DA, Romero E. Reversible thyroid dysfunction with filgrastim. Lancet 1996; 348: 1595-1596.
19. Hoekman K, von Blomberg-van der Flier BM, Wagstaff J, Drexhage HA, Pinedo HM. Reversible thyroid dysfunction during treatment with GM-CSF. Lancet 1991; 338: 541-542.
20. Van Hoef ME, Howell A. Risk of thyroid dysfunction during treatment with G-CSF. Lancet 1992; 340: 1169-1170.
21. Duarte R, De Luis DA, Lopez-Jimenez J, Roy G, Garcia A. Thyroid function and autoimmunity during treatment with G-CSF. Clin Endocrinol (Oxf 1999; 51: 133-134.
22. Ehninger G. German Donor Registry Program. Safeguarding Adult and Pediatric Stem Cell Donors: Basic Science, Clinical, and Ethical Issues Arlington, VA, September 2, 2004.
23. Stroncek DF, Dittmar K, Shawker T, Heatherman A, Leitman SF. Transient spleen enlargement in peripheral blood progenitor cell donors given G-CSF. J Transl Med 2004; 2: 25.
24. Stroncek D, Shawker T, Follmann D, Leitman SF. G-CSF-induced spleen size changes in peripheral blood progenitor cell donors. Transfusion 2003; 43: 609-613.
25. Platzbecker U, Prange-Krex G, Bornhauser M, Koch R, Soucek S, Aikele P et al. Spleen enlargement in healthy donors during G-CSF mobilization of PBPCs. Transfusion 2001; 41: 184-189.
26. Nuamah NM, Goker H, Kilic YA, Dagmoura H, Cakmak A. Spontaneous splenic rupture in a healthy allogeneic donor of peripheral-blood stem cell following the administration of granulocyte colony-stimulating factor (g-csf). A case report and review of the literature, Haematologica 2006; 91 (Suppl 5): ECR08.
27. Falzetti F, Aversa F, Minelli O, Tabilio A. Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor. Lancet 1999; 353: 555.
28. Dincer AP, Gottschall J, Margolis DA. Splenic rupture in a parental donor undergoing peripheral blood progenitor cell mobilization. J Pediatr Hematol Oncol 2004; 26: 761-763.
29. Balaguer H, Galmes A, Ventayol G, Bargay J, Besalduch J. Splenic rupture after granulocyte-colony-stimulating factor mobilization in a peripheral blood progenitor cell donor. Transfusion 2004; 44: 1260-1261.
30. Kasper C, Jones L, Fujita Y, Morgenstern GR, Scarffe JH, Chang J. Splenic rupture in a patient with acute myeloid leukemia undergoing peripheral blood stem cell transplantation. Ann Hematol 1999; 78: 91-92.
31. Pitini V, Ciccolo A, Arrigo C, Aloi G, Micali C, La Torre F. Spontaneous rupture of spleen during periferal blood stem cell mobilization in a patient with breast cancer. Haematologica 2000; 85: 559-560.
32. O'Malley DP, Whalen M, Banks PM. Spontaneous splenic rupture with fatal outcome following G-CSF administration for myelodysplastic syndrome. Am J Hematol 2003; 73: 294-295.
33. Arshad M, Seiter K, Bilaniuk J, Qureshi A, Patil A, Ramaswamy G et al. Side effects related to cancer treatment: CASE 2. Splenic rupture following pegfilgrastim. J Clin Oncol 2005; 23: 8533-8534.
34. Hatzimichael E, Benetatos L, Stebbing J, Kapsali E, Panayiotopoulou S, Bourantas KL. Spontaneous splenic haematoma in a multiple myeloma patient receiving pegfilgrastim support. Clin Lab Haematol 2006; 28: 416-418.
35. Kuendgen A, Fenk R, Bruns I, Dommach M, Schutte A, Engers R et al. Splenic rupture following administration of pegfilgrastim in a patient with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2006; 38: 69-70.
36. Watring NJ, Wagner TW, Stark JJ. Spontaneous splenic rupture secondary to pegfilgrastim to prevent neutropenia in a patient with non-small-cell lung carcinoma. Am J Emerg Med 2007; 25: 247-248.
37. Yoshida I, Matsuo K, Teshima T, Hashimoto D, Tanimoto Y, Harada M et al. Transient respiratory disturbance by granulocyte-colony-stimulating factor administration in healthy donors of allogeneic peripheral blood progenitor cell transplantation. Transfusion 2006; 46: 186-192.
38. Arimura K, Inoue H, Kukita T, Matsushita K, Akimot M, Kawamata N et al. Acute lung injury in a healthy donor during mobilization of peripheral blood stem cells using granulocytecolony stimulating factor alone. Haematologica 2005; 90: ECR10.
39. Makita K, Ohta K, Mugitani A, Hagihara K, Ohta T, Yamane T et al. Acute myelogenous leukemia in a donor after granulocyte colony-stimulating factor-primed peripheral blood stem cell harvest. Bone Marrow Transplant 2004; 33: 661-665.
40. Cavallaro AM, Lilleby K, Majolino I, Storb R, Appelbaum FR, Rowley SD et al. Three to six year follow-up of normal donors who received recombinant human granulocyte colonystimulating factor. Bone Marrow Transplant 2000; 25: 85-89.
41. Tassi C, Tazzari PL, Bonifazi F, Giudice V. Nannetti A, Ricci F et al. Short- and long-term haematological surveillance of healthy donors of allogeneic peripheral haematopoietic progenitors mobilized with G-CSF: A single institution prospective study. Bone Marrow Transplant 2005; 36: 289-294.
42. Anderlini P, Chan FA, Champlin RE, Korbling M, Strom SS. Long-term follow-up of normal peripheral blood progenitor cell donors treated with filgrastim: No evidence.of increased risk of leukemia development. Bone Marrow Transplant 2002; 30: 661-663.
43. Sakamaki S, Matsunaga T, Hirayama Y, Kuga T, Niitsu Y. Haematological study of healthy volunteers 5 years after G-CSF. Lancet 1995; 346: 1432-1433.
44. Smith RE, Bryant J, DeCillis A, Anderson S. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicincyclophosphamide adjuvant therapy for operable breast cancer: The National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol 2003; 21: 1195-1204.
45. Hershman D, Neugut AI, Jacobson JS, Wang J, Tsai WY, McBride R et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst 2007; 99: 196-205.
46. Donadieu J, Boutard P, Bernatowska E, Tchernia G, Couillaud G, Philippe N et al. A European phase II study of recombinant human granulocyte colony-stimulating factor (lenograstim) in the treatment of severe chronic neutropenia in children. Lenograstim Study Group. Eur J Pediatr 1997; 156: 693-700.
47. Dale DC, Cottle TE, Fier CJ, Bolyard AA, Bonilla MA, Boxer LA et al. Severe chronic neutropenia: Treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry. Am J Hematol 2003; 72: 82-93.
48. Hasenclever D, Sextro M. Safety of AlloPBPCT donors: Biometrical considerations on monitoring long term risks. Bone Marrow Transplant 1996; 17 (Suppl 2): S28-S30.
49. Confer DL, Miller JP. Long-term safety of filgrastim (rhG-CSF) administration. Br J Haematol 2007; 137: 77-78.
50. Bacher U, Zander AR. Long-term safety of filgrastim (rhG-CSF) administration: Application of haematopoietic growth factors in healthy individuals. Br J Haematol 2007; 137: 78-79.
51. Rosenthal J, Healey T, Ellis R, Gillan E, Cairo MS. A two-year follow-up of neonates with presumed sepsis treated with recombinant human granulocyte colony-stimulating factor during the first week of life. J Pediatr 1996; 128: 135-137.
52. Storek J, Dawson MA, Maloney DG. Normal T, B, and NK cell counts in healthy donors at 1 year after blood stem cell harvesting. Blood 2000; 95: 2993-2994.
53. Rosenberg PS, Alter BP, Bolyard AA, Bonilla MA, Boxer LA, Cham B et al. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood 2006; 107: 4628-4635.
54. Donadieu J, Leblanc T, Bader Meunier B, Barkaoui M, Fenneteau O, Bertrand Y et al. Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia. Experience of the French Severe Chronic Neutropenia Study Group. Haematologica 2005; 90: 45-53.
55. Nagler A, Korenstein-Ilan A, Amiel A, Avivi L. Granulocyte colony-stimulating factor generates epigenetic and genetic alterations in lymphocytes of normal volunteer donors of stem cells. Exp Hematol 2004; 32: 122-130.
56. Shapira MY, Kaspler P, Samuel S, Shoshan S, Or R. Granulocyte colony stimulating factor does not induce long-term DNA instability in healthy peripheral blood stem cell donors. Am J Hematol 2003; 73: 33-36.
57. Kaplinsky C, Trakhtenbrot L, Hardan I, Reichart M, Daniely M, Toren A et al. Tetraploid myeloid cells in donors of peripheral blood stem cells treated with rhG-CSF. Bone Marrow Transplant 2003; 32: 31-34.
58. Rutella S, Rumi C, Pierelli L, Morosetti R, Sica S, Bonanno G et al. Granulocyte colony-stimulating factor perturbs lymphocyte mitochondrial function and inhibits cell cycle progression. Exp Hematol 2000; 28: 612-625.
59. Hernandez JM, Castilla C, Gutierrez NC, Isidro IM, Delgado M, de las Rivas J et al. Mobilisation with G-CSF in healthy donors promotes a high but temporal deregulation of genes. Leukemia 2005; 19 1088-1091.
60. Dong F, Brynes RK, Tidow N, Welte K, Lowenberg B, Touw IP. Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia. New Engl J Med 1995; 333: 487-493.
61. Ancliff PJ, Gale RE, Liesner R, Hann I, Linch DC. Long-term follow-up of granulocyte colony-stimulating factor receptor mutations in patients with severe congenital neutropenia: Implications for leukaemogenesis and therapy. Br J Haematol 2003; 120: 685-690.
62. Confer D. Adult Allodonor Stem Cell Collection Safety Issues. Safeguarding Adult and Pediatric Stem Cell Donors: Basic Science, Clinical, and Ethical Issues. Arlington, VA, 2004.
63. Bortin MM, D'Amaro J, Bach FH, Rimm AA, van Rood JJ. HLA associations with leukemia. Blood 1987; 70: 227-232.
64. Grupp SA, Frangoul H, Wall D, Pulsipher MA, Levine JE, Schultz KR. Use of G-CSF in matched sibling donor pediatric allogeneic transplantation: a consensus statement from the Children's Oncology Group (COG) Transplant Discipline Committee and Pediatric Blood and Marrow Transplant Consortium (PBMTC) Executive Committee. Pediatr Blood Cancer 2006; 46: 414-421.